Over 160 rare disease patients in India face treatment halts after reaching the ₹50 lakh funding cap. Understand the policy impact and healthcare challenges. The pharmaceutical and healthcare sector closely monitors these policy developments because the market for orphan drugs—medicines designed for rare diseases—is heavily dependent on government-backed procurement and subsidy schemes. Due to the extremely high cost of these therapies, private insurance penetration remains low, and out-of-pocket expenditure is often prohibitive for the average family. Consequently, government policy acts as the primary driver of demand for these high-value medical products. This funding crisis directly affects patient access to critical therapies and highlights the challenges of balancing government health budgets with the high costs of long-term care for rare metabolic disorders. The Lysosomal Storage Disorders Support Society has formally urged the central government to release interim funding for patients suffering from rare genetic metabolic disorders. The request follows a critical situation where the existing ₹50 lakh financial assistance limit, mandated under the National Policy for Rare Diseases, has been exhausted by at least 164 patients. With funds depleted, at least 115 patients—many diagnosed with conditions such as Gaucher and Pompe disease—are currently unable to access the specialized enzyme replacement therapies necessary for their survival.

The Lysosomal Storage Disorders Support Society has urged Prime Minister Modi for additional funding to prevent treatment interruptions for 164 patients, including 115 with ultra-rare lysosomal storage disorders like Gaucher and Pompe disease. The appeal highlights the urgent need for a continuity-of-treatment mechanism, especially for young children affected by these life-threatening conditions.

Recent research highlights the use of integrative genomics, predictive algorithms, and lipidomics to advance understanding of lysosomal storage disorders. These innovative approaches aim to improve diagnosis and treatment strategies for these complex conditions.

Expansion of Clinical Development Cell and gene therapy technologies are being investigated across a broad range of rare diseases, including hemophilia, lysosomal storage disorders, neurological diseases, inherited retinal diseases, muscular disorders, metabolic disorders, and skin diseases. Cell and Gene Therapies in Rare Disorders market is undergoing significant transformation as advances in genetic medicine increasing clinical development activity regulatory approvals the expansion of one time therapeutic approaches create new opportunities across rare disease treatment According to DelveInsight ... Press release - ABNewswire - Cell and Gene Therapies in Rare Disorders Market to Expand as Regulatory Approvals and Pipeline Innovation Accelerate Adoption | DelveInsight - published on openPR.com * Regulatory approvals of LIBMELDY, SKYSONA, HOLOCLAR, UPSTAZA, ROCTAVIAN, and other therapies have helped establish regulatory pathways for additional cell and gene therapy programs. * Multiple companies continue to advance cell and gene therapies for hemophilia A and B, lysosomal storage disorders, neurological disorders, inherited retinal diseases, muscular disorders, metabolic diseases, and other rare conditions.

The rising incidence of cancer, diabetes, rare genetic diseases, and other chronic conditions is strengthening demand for cell and gene therapies in Mexico. Gene therapies are gaining attention for inherited disorders such as hemophilia, sickle cell anemia, and lysosomal storage diseases, while ... The rising incidence of cancer, diabetes, rare genetic diseases, and other chronic conditions is strengthening demand for cell and gene therapies in Mexico. Gene therapies are gaining attention for inherited disorders such as hemophilia, sickle cell anemia, and lysosomal storage diseases, while stem cell and chimeric antigen receptor T-cell (CAR-T) therapies are advancing oncology treatment. Mexico’s cell and gene therapy sector is gaining momentum amid rising disease burdens, expanding biotech infrastructure, streamlined approvals and... Therapy type: Cell therapy, including pluripotent stem cells, cancer stem cells, adult stem cells, T-cells, natural killer cells, and other non-stem-cell therapies; and gene therapy. Indication: Cardiovascular diseases, oncology disorders, genetic disorders, infectious diseases, neurological disorders, and other conditions. Key Topics Covered: 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Mexico Cell and Gene Therapy Market - Introduction 4.1 Overview 4.2 Market Dynamics 4.3 Industry Trends 4.4 Competitive Intelligence 5 Mexico Cell and Gene Therapy Market Landscape 5.1 Historical and Current Market Trends (2020-2025) 5.2 Market Forecast (2026-2034) 6 Mexico Cell and Gene Therapy Market - Breakup by